BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF
BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF: BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, chidamide, and G-CSF
Study summary
The purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age 18-75 years
2. Confirmed diagnosis of R/R AML
3. Adequate organ function: TBIL ≤2×ULN; ALT/AST ≤2.5×ULN; Cr ≤ULN or Ccr ≥50 mL/min
4. ECOG performance status ≤2
5. Life expectancy ≥4 months
6. No severe allergic history
7. Not participating in other interventional trials during study
8. Signed informed consent -
Exclusion Criteria:
1. Hypersensitivity to any study drug
2. Dysphagia or uncontrolled gastrointestinal disease impairing oral intake
3. Acute promyelocytic leukemia (APL)
4. Prior treatment with EZH1/2 inhibitors
5. Allogeneic hematopoietic stem cell transplantation within 6 months
6. Participation in another interventional trial within 4 weeks
7. Smoking and excessive drinking have affected the evaluation of the test results;
8. Undergone major organ surgery within the previous 6 weeks and whose recovery was not complete
9. Severe chronic respiratory disease requiring continuous oxygen
10. Clinically significant cardiac, renal, hepatic, neurologic, or endocrine disease; Child-Pugh B/C cirrhosis
11. Active uncontrolled infection including HBV, HCV, HIV, syphilis
12. Pregnant or breastfeeding women; women planning pregnancy during study
13. The patients deemed unsuitable by the researchers to participate in this study. -
Primary outcome measure(s)
Composite Complete Remission Rate (CRc) — one year after treatment CRc = Complete Remission (CR) + Complete Remission with incomplete hematologic recovery (CRi)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.